Ultragenyx Pharma (RARE) Misses Q2 EPS by 51c; Reaffirms Product Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update
July 28, 2022 4:01 PM EDTSecond quarter 2022 total revenue of $89.3 million and Crysvita® revenue in Ultragenyx territories1 of $64.0 million
Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 million
Expanded clinical pipeline through acquisition of GeneTx and global rights to UX111 for Sanfilippo syndrome
Completed $500.0 million sale of a capped 30% of royalty interest on the future sales of Crysvita in the United States and Canada
NOVATO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:... More
